About Abogen
Founded in 2019, Abogen is a clinical-stage biotechnology company advancing mRNA-based science and technology to create a new generation of transformative medicine. With an industry-leading proprietary mRNA technology platform and nanoparticle delivery system, we are among few companies in the world with the full capability for the development of mRNA-based therapeutics, from mRNA sequence design to LNP formulation development and large-scale manufacturing. We strive to conquer unmet medical needs by exploring innovative mRNA-based alternatives to traditional therapies. With this vision in mind, we have built a diversified product pipeline, spanning various disease areas and therapies from the prophylactic vaccines to immune-oncology and protein replacement.
3 +
Years Of
Progress
1
Product Approved
to Market
1
Pipeline Product by
Clinical Stage
3
R&D, Production,
and Operation Sites
400 +
Team Members
50 %+
Employees with
Advanced Degrees
70 +
Issued
International Patents